



Application of:

BROWN

Serial No. 10/625,866

Filing Date: July 22, 2003

For: *Angiogenesis Inhibition by
Cephalotaxine Alkaloids,
Derivatives, Compositions and Uses
Thereof*

JFW

PATENT
Attorney Docket No.: A-72359/RFT/THR
Attorney File No.: 468899-00037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Examiner: Not Yet Assigned

Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated: August 30, 2004

Signed: 
Brent Yonehara

**INFORMATION DISCLOSURE STATEMENT
AND
STATEMENT OF RELATEDNESS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Off. 1, 8/5/2003, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

Serial No.: 10/625,866
Filing Date: July 22, 2003

Further, in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and as required by M.P.E.P. § 2001.06(b), Applicant notes that the present application is related to the following pending patent applications:

1. U.S.S.N. 10/769,638, filed January 30, 2004, which is a divisional of US Patent No. 6,734,178 (cite A3 on attached form PTO/SB/8A);
2. U.S.S.N. 10/273,801 (a continuation-in-part of U.S.S.N. 09/834,077, filed April 12, 2001, now U.S. Patent No. 6,630,173 B2, (cite A2 on attached form PTO/SB/8A));
3. U.S.S.N. 10/631,106, filed July 31, 2003 (Publication No 2004/0047918), which is a divisional of US Patent No. 6,630,173 (cite A2 on attached form PTO/SB/8A);
4. U.S.S.N. 09/996,354, filed October 31, 2001 (Publication No. 2002/0123469);
5. U.S.S.N. 10/616,178, filed July 8, 2003 (Publication No. 2004/0082788); and
6. U.S.S.N. 10/617,927, filed July 10, 2003 (Publication No. 2004/0082565).

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a

Serial No.: 10/625,866
Filing Date: July 23, 2003

first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.

While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 468899-00037 (A-72359/RFT/THR)).

RESPECTFULLY SUBMITTED,


DORSEY & WHITNEY LLP

Dated: August 27, 2004 By: T - H. R
Customer Number: 32940
Traci H. Ropp, Reg. No. 44,307 for
Dorsey & Whitney LLP
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
(415) 781-1989 (telephone)
(415) 398-3249 (facsimile)

Richard F. Trecartin, Reg. No. 31,801

Attachments: Form PTO/SB/8A-B, substitute for Form PTO-1449
International Search Report
13 cited references
Return Postcard

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/626,866
				Filing Date	July 22, 2003
				First Named Inventor	BROWN, Dennis M.
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	A-72359/RFT/THR (468899-00037)



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,152,214	05-01-1979	Delfel et al.	
	A2	6,630,173 B2	10-07-2003	Brown	
	A3	6,734,178 B2	05-11-2004	Brown	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	WO 95/29242	11-02-1995	The Children's Medical Center Corporation	T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	C1	AUSPRUNK, D.H., et al., "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels During Tumor Angiogenesis," <i>Microvasc. Res.</i> 14(1):53-65 (Jul. 1977).			
	C2	FIDLER, J., et al., "The implications of angiogenesis for the biology and therapy of cancer metastasis," <i>Cell</i> 79(2):185-188 (Oct. 1994).			
	C3	FOLKMAN, J., "How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A.," <i>Cancer Res.</i> 46(2):467-473 (Feb. 1986).			
	C4	FOLKMAN, J., "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> 19:331-358 (1974).			
	C5	FOLKMAN, J., "What is the evidence that tumors are angiogenesis dependent?," <i>J. Natl. Cancer Inst.</i> 82(1):4-6 (Jan. 1990).			
	C6	GASPARINI, G., et al., "Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool," <i>J. Clin. Oncol.</i> 13(3):765-782 (Mar. 1995).			
	C7	O'REILLY, M., et al., "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma," <i>Cell</i> 79(2):315-328 (Oct. 1994).			
	C8	POWELL, R.G., "Antitumor alkaloids for <i>Cephalotaxus harringtonia</i> : structure and activity," <i>J. Pharm. Sci.</i> 61(8):1227-1230 (Aug. 1972).			
	C9	STORGARD, C.M., et al., "Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an avβ3 Antagonist," <i>J. Clin. Invest.</i> 103(1):47-54 (Jan. 1999).			
	C10	WALSH, D.A., et al., "Angiogenesis in the Pathogenesis of Inflammatory Joint and Lung Diseases," <i>Arthritis Res.</i> 3(3):147-153 (Feb. 2001).			
	C11	WEIDNER, N., et al., "Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma," <i>New Eng. J. Med.</i> 324(1):1-8 (Jan. 1991).			
	C12	WILKINSON-BERKA, J.L., et al., "The Interaction Between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes," <i>J. Vasc. Res.</i> 38(6):527-535 (Nov. - Dec. 2001).			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2